



Contacts: Bret L. Udem
Media Relations
Tel. (425) 493-2293
Fax. (425) 493-2010

FOR RELEASE
December 6, 2005

COMBIMATRIX MOLECULAR DIAGNOSTICS TO TEST FOR INFLUENZA

Service will enable identification of (H5N1) Bird Flu

Newport Beach, Calif. – (BUSINESS WIRE) – December 6, 2005 – Acacia Research Corporation (Nasdaq: CBMX:ACTG) announced today that its CombiMatrix group's wholly owned subsidiary, CombiMatrix Molecular Diagnostics (CMD), is now offering influenza testing services utilizing the CombiMatrix Influenza DNA-based microarray. The array will enable genetic identification of the specific type of influenza including the (H5N1) bird flu as well as others.

This influenza analysis may be run on animal as well as human samples for Research Use Only (RUO). At the current time, the influenza array is not an FDA approved product, nor will it be run in a CLIA (Clinical Laboratory Improvement Amendments) – certified facility, as CMD is currently awaiting laboratory certification. Those interested in having samples tested will be provided specimen collection kits with appropriate instructions.

“Although our primary focus is on gene-based cancer diagnostics, the flexibility of our technology enables us to rapidly address public health concerns such as viral diseases that have the potential to cause pandemics,” stated Matt Watson, CEO of CMD. “We are already in discussions with many domestic and international agencies and we believe this will be a powerful tool for monitoring of the H5N1 Asian Bird Flu.”

Dr. Amit Kumar, President and CEO of CombiMatrix Corporation said, “We are constantly reading reports of birds as well as humans who have been infected with or have died from an influenza. Often these reports indicate that conventional testing was not able to identify the causative influenza strain. Through our molecular diagnostics laboratory, CMD, we wanted to offer our testing services to those who have a need for a very powerful and comprehensive testing service for influenza.”

For further information on this service please contact CombiMatrix Molecular Diagnostics at (949) 753.0624 or by email at fluchip@cmdiagnostics.com.

COMBIMATRIX INFLUENZA ARRAY

CombiMatrix's Influenza Microarray is a member of the CombiMatrix CatalogArray™ product line and can detect and accurately type flu strains using a protocol that requires less than four hours start to finish. This new microarray can identify H5N1 bird flu as well as provide information on mutations and novel strains of flu not yet seen. The Influenza array provides very-high-resolution genotype information on any given flu strain as well as information on novel strains of flu produced by rapid mutation or recombination between multiple strains of flu. It is designed to work on samples from humans as well as from birds, pigs, horses, dogs, and various other animals.

CombiMatrix CatalogArray's contain *in situ* synthesized oligonucleotides, prepared using CombiMatrix's patented virtual-flask technology. Sensitivity and performance metrics are available from the company's web site and at www.customarray.com.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 34 patent portfolios, which include over 130 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, high resolution optics, image resolution enhancement, interactive data sharing, interactive television, hearing aid ECS, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.

Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia Research-CombiMatrix (Nasdaq: CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based

upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.